| pubmed-article:2605121 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2605121 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
| pubmed-article:2605121 | lifeskim:mentions | umls-concept:C0003339 | lld:lifeskim |
| pubmed-article:2605121 | lifeskim:mentions | umls-concept:C0348026 | lld:lifeskim |
| pubmed-article:2605121 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:2605121 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:2605121 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:2605121 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2605121 | pubmed:dateCreated | 1990-2-16 | lld:pubmed |
| pubmed-article:2605121 | pubmed:abstractText | Thirty-six cases of acute myeloid leukaemia (AML) were tested with a large battery of monoclonal antibodies (moAbs) detecting surface markers normally expressed by myelomonocytic, T and B lymphoid, megakaryocytic and erythroid lineages. Differences in antigenic expression were observed among the various FAB subgroups: HLA-class II molecules were found in almost all AML cases but not in the promyelocytic subgroup (M3); CD14 and CD36 antigens were detected in monocytic leukaemias (M4 and M5); the CD34 moAb (MY10) recognizing an epitope described on myeloid stem cells was positive in 88% of the M1 and 80% of the M3 cases. By a multivariate analysis, only the CD14b (MY4) discriminated significantly between M1-M2 and M4-M5 subgroups. Using Cox's model to assess the prognostic importance of variables including immunophenotyping on survival, we undertook a one by one analysis and found that the presence of CD17 antigen predicted for a shorter survival (P = 0.03). In addition this marker appeared more significant than other clinical and biological parameters. | lld:pubmed |
| pubmed-article:2605121 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2605121 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2605121 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2605121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2605121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2605121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2605121 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2605121 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:2605121 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:2605121 | pubmed:author | pubmed-author:MichelAA | lld:pubmed |
| pubmed-article:2605121 | pubmed:author | pubmed-author:BoucheixCC | lld:pubmed |
| pubmed-article:2605121 | pubmed:author | pubmed-author:DebrePP | lld:pubmed |
| pubmed-article:2605121 | pubmed:author | pubmed-author:ChastangCC | lld:pubmed |
| pubmed-article:2605121 | pubmed:author | pubmed-author:LeblondVV | lld:pubmed |
| pubmed-article:2605121 | pubmed:author | pubmed-author:Merle-BeralHH | lld:pubmed |
| pubmed-article:2605121 | pubmed:author | pubmed-author:Nguyen Cong... | lld:pubmed |
| pubmed-article:2605121 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2605121 | pubmed:volume | 73 | lld:pubmed |
| pubmed-article:2605121 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2605121 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2605121 | pubmed:pagination | 323-30 | lld:pubmed |
| pubmed-article:2605121 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:meshHeading | pubmed-meshheading:2605121-... | lld:pubmed |
| pubmed-article:2605121 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2605121 | pubmed:articleTitle | Diagnostic and prognostic significance of myelomonocytic cell surface antigens in acute myeloid leukaemia. | lld:pubmed |
| pubmed-article:2605121 | pubmed:affiliation | Département d'Hématologie et Unité, Claude Bernard C20, Hôpital, Pitié-Salpêtrière, Paris, France. | lld:pubmed |
| pubmed-article:2605121 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2605121 | lld:pubmed |
